Results per Page:
New Science Spotlight Articles
Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
February 27, 2026
Extramedullary disease shapes toxicity risk in BCMA CAR T therapy
From the Gauthier Group, Clinical Research Division
For many blood cancer patients, CAR T-cell therapy is game-changing
In this episode of From Bench to Bedside and Beyond, Dr. Mazyar Shadman explains why CAR T-cell therapy should be considered for patients who relapse
Gratitude for life-saving care at Fred Hutch leads to endowed chair
Dr. Madhav Dhodapkar is the recipient of the Milton B. Rubin Family Endowed Chair
New insights into T cell function in multiple myeloma patients
From the Newell Lab, Vaccine and Infectious Disease Division
Giving that feels ‘beyond meaningful’
The Steinberg family honors the memory of loved ones by celebrating and supporting a profession that takes caring to another level
Multiple myeloma is treatable, not curable. Is that set to change?
Some experts believe a ‘functional cure’ is already within reach
Nuanced and far-reaching effects of gamma secretase inhibition in the multiple myeloma patients
From the Damian Green Lab, in collaboration with the Geoff Hill and Riddell Labs, Translational Sciences and Therapeutics Division and David Coffey, Division of Myeloma, at the University of Miami
When it comes to cancer trials, what’s the (end)point?
New endpoint in multiple myeloma could mean faster drug approvals. Are more endpoint tweaks on the way?
Una dosis de bortezomib por semana es suficiente para tratar el mieloma múltiple
Del Dr. Rahul Banerjee, División de Investigación Clínica
Once-weekly bortezomib is enough to treat multiple myeloma
From Dr. Rahul Banerjee, Clinical Research Division
‘What are the odds?’
Light chain amyloidosis patient participates in clinical trial that ends up helping her sister-in-law
Multiple myeloma research to be presented at American Society of Hematology annual meeting
Dr. Rahul Banerjee to share insights on reducing financial toxicity, time toxicity and side effects of treatment
Something new and something old synergize to limit multiple myeloma relapse
From the Hill Lab, Translational Science and Therapeutics Division